Outer membrane protein I of Pseudomonas aeruginosa is a target of cationic antimicrobial peptide/protein

Yu-Min Lin1, Shih-Jung Wu, Ting-Wei Chang

  • 1Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.

Insights

Pseudomonas aeruginosa outer membrane protein I (OprI) mediates susceptibility to human ribonuclease 7 (hRNase 7) and other cationic antimicrobial peptides (AMPs). This discovery reveals a new target for developing drugs against antibiotic-resistant bacteria.

Area of Science:

  • Microbiology and Immunology
  • Bacterial Pathogenesis
  • Antimicrobial Drug Discovery

Background:

  • Cationic antimicrobial peptides/proteins (AMPs) are crucial for innate immunity against microbial infections.
  • Pseudomonas aeruginosa is a significant opportunistic pathogen, often exhibiting antibiotic resistance.
  • Lipopolysaccharide (LPS) is typically considered the primary binding site for cationic AMPs on Gram-negative bacteria.

Purpose of the Study:

  • To identify the specific target of human ribonuclease 7 (hRNase 7) and alpha-helical cationic AMPs on Pseudomonas aeruginosa.
  • To elucidate the mechanism by which OprI influences bacterial susceptibility to these antimicrobial agents.
  • To explore OprI as a potential therapeutic target for combating antibiotic-resistant infections.

Main Methods:

  • Investigated the role of outer membrane protein I (OprI) in P. aeruginosa susceptibility to hRNase 7 and alpha-helical cationic AMPs.
  • Assessed the inhibitory effects of exogenous OprI and anti-OprI antibodies on antimicrobial activity.
  • Analyzed the consequences of OprI modification and internalization by hRNase 7 on bacterial membrane permeability and metabolite leakage.
  • Predicted the structural features of OprI involved in binding and anchoring.

Main Results:

  • Outer membrane protein I (OprI), not lipopolysaccharide, was identified as the key factor determining P. aeruginosa susceptibility to hRNase 7 and alpha-helical cationic AMPs.
  • Antimicrobial activity was significantly inhibited by the presence of OprI or antibodies targeting OprI.
  • hRNase 7-mediated modification and internalization of OprI led to increased bacterial membrane permeability and metabolite release.
  • OprI possesses structural elements, including an N-terminal loop and a C-terminal lysine, facilitating binding and anchoring.

Conclusions:

  • OprI represents a novel target for alpha-helical cationic AMPs, offering a new mechanism of antimicrobial action against P. aeruginosa.
  • Targeting OprI could be a viable strategy for developing new therapeutics against antibiotic-resistant bacterial infections.
  • These findings challenge the traditional view of LPS as the sole initial binding site for cationic AMPs.

Related Concept Videos

Antimicrobial Proteins01:23

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Structure of Porins01:21

Structure of Porins

Mitochondria, chloroplasts, and gram-negative bacteria have transmembrane, beta-barrel proteins called porins to mediate the free diffusion of ions and metabolites across the membrane. Mitochondrial porin precursors contain conserved amino acid sequences called beta signals at their C-terminal. Beta signals have a  motif of PoXGXXHyXHy (Po-Polar, X-Any amino acid, G-Glycine, Hy-LargeHydrophobic), which are crucial for precursor recognition to initiate precursor assembly. Beta-barrel precursors...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Multi-pass Transmembrane Proteins and β-barrels01:09

Multi-pass Transmembrane Proteins and β-barrels

In multi-pass transmembrane proteins, the polypeptide chain crosses the membrane more than once. The transmembrane polypeptide chain either forms an α-helix or β-strand structure. α-Helix containing multi-pass transmembrane proteins are ubiquitous, whereas β-strand containing ones are mainly found in gram-negative bacteria, mitochondria, and chloroplasts.
α-Helix containing multi-pass transmembrane proteins
Multi-pass transmembrane proteins such as G-protein-linked receptors (GPCRs) and...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...